Quantcast

Latest Anti-angiogenics Stories

2012-05-01 21:25:08

American Health Assistance Foundation Calls for Greater Investment in Research to Halt Eye Disease This week, the second-year results of an important clinical trial on age-related macular degeneration (AMD), known as the Comparison of AMD Treatments Trials (or CATT), were published in the journal Ophthalmology. Researchers found that two drugs known as Avastin (bevacizumab) and Lucentis (ranibizumab), commonly used to treat the wet form of AMD, were similarly effective in maintaining...

2010-10-06 11:14:00

(Ivanhoe Newswire) "“ Age-related macular degeneration (AMD) is the leading cause of blindness for people over fifty. There are two treatments for AMD, although there is no cure, these treatments reduce the impact that macular degeneration has on vision. The two drugs include Bevacizumab (Avastin) and Ranibizumab (Lucentis). Scientists, for the first time, have discovered that there may not be any difference in the efficacy of these drugs- one is not better than the other. AMD affects...

2010-10-01 14:27:04

Researchers from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have conducted a study that failed to show a difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). The study, which appears currently on-line in Eye, is believed to be the first study to describe one-year outcomes of a prospective, double-masked, randomized clinical trial directly comparing bevacizumab to...

2010-03-08 16:57:20

Use of medications injected directly into the eye appears to be an increasingly common treatment for age-related macular degeneration in one region of Canada, but only a small proportion of ophthalmologists perform the procedure, according to a report in the March issue of Archives of Ophthalmology, one of the JAMA/Archives journals. Age-related macular degeneration is the leading cause of blindness in Western nations, according to background information in the article. The development of...

2010-02-16 07:00:00

WALTHAM, Mass., Feb. 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that both Genentech/Novartis Ophthalmics' Lucentis and Regeneron/Bayer's aflibercept will earn Decision Resources' proprietary clinical gold standard status for wet age-related macular degeneration in 2013 and 2018. A unique future gold standard cannot be identified because neither thought-leader opinion nor available clinical...

2009-10-10 07:50:30

Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). The study, which appears currently on-line in the American Journal of Ophthalmology, is the first to report early outcomes of a prospective, double-masked, randomized, controlled trial...

2008-08-29 03:00:10

WASHINGTON - What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing $60 per treatment and the other $2,000? In the case of Genentech Inc., nothing. The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance - or cooperate with - a National Eye Institute study comparing the...

2008-08-28 06:01:10

The National Institute for Health and Clinical Excellence has recommended Novartis's Lucentis as a cost-effective therapy for all eligible patients with wet age-related macular degeneration. The announcement is said to be an important development for patients because the National Institute for Health and Clinical Excellence (NICE) determines access to medicines in England and Wales based on agreed standards of cost-effectiveness. The final guidance comes at the end of a rigorous review...

2008-08-28 03:00:19

THOUSANDS of people all over the country will be able to receive sightsaving drugs thanks to a campaign spearheaded by three Warwickshire patients. The drug Lucentis will now be available on the NHS to anyone with 'wet' macular degeneration - an eye disease which sends sufferers blind. The National Institute for Health and Clinical Excellence (Nice) recommended doctors use the drug because it could cut the cost of treating a patient by more than pounds 8,000 over ten years. Campaigners...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.